202 83

Full metadata record

DC FieldValueLanguage
dc.contributor.author권휘안-
dc.date.accessioned2022-03-11T07:07:29Z-
dc.date.available2022-03-11T07:07:29Z-
dc.date.issued2020-06-
dc.identifier.citationTRANSLATIONAL ANDROLOGY AND UROLOGY, v. 9, no. 3, page. 983-985en_US
dc.identifier.issn2223-4683-
dc.identifier.issn2223-4691-
dc.identifier.urihttps://tau.amegroups.com/article/view/40828/html-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/169016-
dc.description.abstractEditorial Materialen_US
dc.description.sponsorshipThis study was supported by the Korean National Cancer Center (NCC1810866).en_US
dc.language.isoenen_US
dc.publisherAME PUBL COen_US
dc.subjectCISPLATIN-INELIGIBLE PATIENTSen_US
dc.subjectSINGLE-ARMen_US
dc.subjectMULTICENTERen_US
dc.subjectCARCINOMAen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectPEMBROLIZUMABen_US
dc.subjectATEZOLIZUMABen_US
dc.subjectGEMCITABINEen_US
dc.subjectPACLITAXELen_US
dc.titleOptimizing frontline therapy in advanced urothelial canceren_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume9-
dc.identifier.doi10.21037/tau.2020.04.03-
dc.relation.page983-985-
dc.relation.journalTRANSLATIONAL ANDROLOGY AND UROLOGY-
dc.contributor.googleauthorKwon, Whi-An-
dc.contributor.googleauthorSeo, Ho Kyung-
dc.relation.code2020052424-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkein917-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE